share_log

iBio Inc | 10-K/A: Annual report (Amendment)

iBio Inc | 10-K/A: Annual report (Amendment)

iBio Inc | 10-K/A:年度報表(修正版)
美股SEC公告 ·  09/25 04:17

牛牛AI助理已提取核心訊息

iBio Inc, a biotechnology company specializing in AI-driven antibody drug discovery, has reported a net loss from continuing operations of approximately $15.4 million, or $4.03 per share, for the fiscal year ended June 30, 2024. This represents a significant reduction from the previous year's net loss of approximately $29.3 million, or $47.88 per share. The company's total operating expenses also decreased to approximately $16.9 million from $29.3 million in the previous year, primarily due to reduced research and development (R&D) and general and administrative (G&A) expenses. iBio's R&D expenses decreased by about 50% to $5.2 million, while G&A expenses fell by 39% to $11.7 million. The company's revenue for the year was reported at $0.2 million, related to research activities and license fees. iBio...Show More
iBio Inc, a biotechnology company specializing in AI-driven antibody drug discovery, has reported a net loss from continuing operations of approximately $15.4 million, or $4.03 per share, for the fiscal year ended June 30, 2024. This represents a significant reduction from the previous year's net loss of approximately $29.3 million, or $47.88 per share. The company's total operating expenses also decreased to approximately $16.9 million from $29.3 million in the previous year, primarily due to reduced research and development (R&D) and general and administrative (G&A) expenses. iBio's R&D expenses decreased by about 50% to $5.2 million, while G&A expenses fell by 39% to $11.7 million. The company's revenue for the year was reported at $0.2 million, related to research activities and license fees. iBio also highlighted its strategic focus on AI and machine learning to advance its preclinical pipeline in immune-oncology and cardiometabolic diseases. The company has not declared any cash dividends on its common stock and has undergone a reverse stock split to improve its stock price. iBio's future plans include leveraging strategic collaborations, advancing in-house programs, and investing in its AI-technology platform to enhance drug discovery and development. The company also completed the sale of its CDMO facility for $8.5 million and settled its obligations with Woodforest, resulting in a more streamlined operation focused on its core mission.
生物技術公司ibio inc 專注於人工智能驅動的抗體藥物發現,報告截至2024年6月30日的財政年度持續運營淨損失約1540萬美元,或每股4.03美元。這較上一年約2930萬美元,每股47.88美元的淨虧損有顯著減少。公司的總營業費用也從上一年的約2930萬美元減少至約1690萬美元,主要是由於減少了研發和一般行政費用。ibio的研發費用下降了約50%至520萬美元,而一般行政費用下降了39%至1170萬美元。公司年度營業收入報告爲20萬美元,與研究活動和許可費有關。ibio還強調了其戰略重點是人工智能和機器學習,以推動免疫腫瘤學和心臟代謝疾病的臨床前候選藥物管線。公司尚未宣佈對普通股的任何...展開全部
生物技術公司ibio inc 專注於人工智能驅動的抗體藥物發現,報告截至2024年6月30日的財政年度持續運營淨損失約1540萬美元,或每股4.03美元。這較上一年約2930萬美元,每股47.88美元的淨虧損有顯著減少。公司的總營業費用也從上一年的約2930萬美元減少至約1690萬美元,主要是由於減少了研發和一般行政費用。ibio的研發費用下降了約50%至520萬美元,而一般行政費用下降了39%至1170萬美元。公司年度營業收入報告爲20萬美元,與研究活動和許可費有關。ibio還強調了其戰略重點是人工智能和機器學習,以推動免疫腫瘤學和心臟代謝疾病的臨床前候選藥物管線。公司尚未宣佈對普通股的任何現金分紅,並進行了一次股票質押拆分,以提高股價。ibio的未來計劃包括利用戰略合作伙伴關係,推進內部項目,並投資於其人工智能技術平台,以增強藥物發現和開發。公司還以850萬美元完成了其CDMO設施的出售,並與Woodforest解決了其義務,使其更專注於以核心使命爲重點的簡化運營。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。